Transcriptomics

Dataset Information

0

Expression data from primary mouse Emu-myc B-cell lymphoma.


ABSTRACT: We are interested in genetic programs and mutations which impact on tumor development and sensitivity to anticancer therapies. Utilizing Emu-myc transgenic mice, which spontaneously develop aggressive B-cell lymphomas, we aimed here to study the effects of drug responses in vivo. For that purpose, primary lymphomas from the Emu-myc transgenic mice were transplanted in several immunocompetent recipients and exposed to a single dose Cyclophosphamide (CTX), a standard component of chemotherapeutic regimens used to treat human B-cell lymphomas. Approximately one half of recipient mice are cured with this treatment (Never Relapse Lymphomas, NR), while in other half lymphomas relapse over time (Relapse Prone Lymphomas, RP), allowing us to treat these relapsed mice with progressively shorter durations of remission into full-blown clinical resistance (Resistant Lymphomas, RES). Looking at the differences between NR, RP and RES lymphomas, each in therapy-naive state or after drug challenge, we aimed here to decipher the genetic and biochemical components determining the susceptibility of lymphoma cells to respond to standard chemotherapeutic drugs.

ORGANISM(S): Mus musculus

PROVIDER: GSE134751 | GEO | 2020/03/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-12-31 | GSE38428 | GEO
2020-01-21 | GSE132721 | GEO
2019-07-04 | GSE116905 | GEO
2013-07-04 | E-GEOD-44355 | biostudies-arrayexpress
2011-11-21 | E-GEOD-31099 | biostudies-arrayexpress
| PRJNA167838 | ENA
2016-07-22 | E-GEOD-49356 | biostudies-arrayexpress
2024-06-01 | GSE183695 | GEO
2019-01-12 | GSE124910 | GEO
2007-11-06 | E-GEOD-6980 | biostudies-arrayexpress